Erythrocyte and Platelet Phospholipid Fatty Acids as Markers of Advanced Non-Small Cell Lung Cancer: Comparison with Serum Levels of Sialic Acid, TPS and Cyfra 21-1

By de Castro Javier   Rodriguez Marina   Martinez-Zorzano Vicenta   Hernandez-Hernandez Angel   Llanillo Marcial   Sanchez-Yague Jesus  

Cancer Investigation, Vol. 26, Iss. 4, 2008-05 ,pp. : 407-418

Informa Healthcare

Access to resources Recommend Favorite

Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy

By                      

Oncology Letters, Vol. 11, Iss. 1, 2016-01 ,pp. : 723-730

Spandidos Publications

Access to resources Recommend Favorite

Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases

By Song Zhengbo   Zhang Yiping  

Medical Oncology, Vol. 31, Iss. 4, 2014-04 ,pp. : 1-4

Humana Press, Inc

Access to resources Recommend Favorite

ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer

By                        

Experimental and Therapeutic Medicine, Vol. 2, Iss. 5, 2011-01 ,pp. : 811-815

Spandidos Publications

Access to resources Recommend Favorite

Phase II study of liarozole in advanced non-small cell lung cancer

By O'Byrne K.J.   Han C.   Mitchell K.   Lane D.   Carmichael J.   Harris A.L.   Talbot D.C.  

European Journal of Cancer, Vol. 34, Iss. 9, 1998-08 ,pp. : 1463-1466

Elsevier

Access to resources Recommend Favorite